AbbVie has begun construction on a $70 million expansion of its AbbVie Bioresearch Center (ABC) in Worcester, Massachusetts, reinforcing its role as a hub for biologics research, development, and manufacturing. The move comes just one day after the company broke ground on $195 million new Active Pharmaceutical Ingredient (API) facility in North Chicago, Illinois, underscoring AbbVie’s accelerated pace of investment in U.S. pharmaceutical manufacturing.
The Worcester project is part of AbbVie’s broader commitment to invest more than $10 billion over the next decade to expand its U.S. operations. The expansion will add biologics manufacturing areas as well as a three-story building that includes laboratory, warehouse, and office space. The new facilities will enable faster transfer of select oncology products from Europe to the U.S. market, strengthening domestic production capacity for both current and next-generation treatments in oncology and immunology.
“For more than three decades, ABC has been at the forefront of scientific innovation and biologics manufacturing,” said Azita Saleki-Gerhardt, Ph.D., executive vice president and chief operations officer at AbbVie. “This investment will further expand AbbVie’s biologics manufacturing capacity and position ABC to build upon its impressive track record of developing, manufacturing, and launching next-generation complex biologic medicines that improve the lives of millions of patients worldwide.”
Jobs
The project will create new jobs in Massachusetts and add to AbbVie’s already significant U.S. presence. The company employs 28,000 people nationwide, including more than 2,000 in Massachusetts, and supports over 6,000 jobs across 11 manufacturing sites in the country.
Yesterday, Sept. 29, 2025, AbbVie broke ground in North Chicago on a state-of-the-art API facility. The project is designed to enhance the company’s ability to produce raw pharmaceutical ingredients for critical therapies. Together, the Worcester and North Chicago projects highlight AbbVie’s commitment to strengthening the U.S. pharmaceutical supply chain. They also expand global access to advanced medicines.
Factsheet: AbbVie Bioresearch Center Expansion (Worcester, MA)
Project Overview
Investment: $70 million
Scope: Additional biologics manufacturing areas; three-story building with laboratory, warehouse, and office space
Purpose: Expand U.S. biologics manufacturing capacity; expedite transfer of select oncology products from Europe
Local Impact: New jobs created at the Worcester site
Broader Commitment: Part of AbbVie’s pledge to invest over $10 billion in U.S. facilities over the next decade
AbbVie U.S. Presence: 28,000 employees nationwide; 2,000+ in Massachusetts; 6,000+ supported across 11 manufacturing sites
Recent Development: Groundbreaking of North Chicago API facility (Sept. 29, 2025)
